Mendes A F, Caramona M M, Lopes M C
Laboratório de Farmacologia, Faculdade de Farmácia, Universidade de Coimbra, Portugal.
J Pharm Pharmacol. 1996 Mar;48(3):302-5. doi: 10.1111/j.2042-7158.1996.tb05921.x.
The aim of this work was to compare the subcellular distribution of the oestrogen receptor from the uteri of rats treated with vehicle alone (control group), oestradiol or one of the anti-oestrogenic drugs tamoxifen and ZD 182,780. The nuclear, microsomal and cytosolic oestrogen receptor contents were evaluated by an immunoenzymatic method ("ER-EIA" kit from Abbott Laboratories) and the results in each fraction were expressed as a percentage of the total number of receptors. Parallel studies were performed to assess the uterotrophic effect of these drugs and to assess that they had reached the uterus. In the control group, we found that the oestrogen receptor was distributed mainly between the microsomal (29.1 +/- 1.3%) and cytosolic (68.1 +/- 0.9%) fractions, with only a small amount located in the nucleus (2.8 +/- 0.5%). When oestradiol was administered, the oestrogen receptor distribution was: nuclear 11.7 +/- 2.0, microsomal 15.5 +/- 1.3 and cytosolic 72.8 +/- 3.3% and, in the tamoxifen group, the results were: nuclear 18.5 +/- 1.5, microsomal 26.0 +/- 3.1 and cytosolic 55.5 +/- 3.4%, which shows a relative shift both to the control and the oestradiol-treated groups. In the uteri of rats treated with ZD 182,780 the results were very similar to those obtained in the control group. Our results indicate that the subcellular distribution of the oestrogen receptor varies according to the drug administered and that this receptor may not be located in a single subcellular compartment. Moreover, the nuclear uptake of the ZD 182,780-oestrogen receptor complex seems to be blocked, possibly due to impaired receptor dimerization. In the case of tamoxifen, the intracellular transport of the receptor also seems to be blocked, probably due to the nuclear retention of the receptor, thus suggesting that tamoxifen must impair the oestrogen receptor function on a step subsequent to the receptor dimerization.
本研究的目的是比较单独给予赋形剂(对照组)、雌二醇或抗雌激素药物他莫昔芬和ZD 182,780之一处理的大鼠子宫中雌激素受体的亚细胞分布。通过免疫酶法(雅培实验室的“ER-EIA”试剂盒)评估细胞核、微粒体和胞质中的雌激素受体含量,各组分的结果以受体总数的百分比表示。进行了平行研究以评估这些药物的子宫营养作用,并评估它们是否已到达子宫。在对照组中,我们发现雌激素受体主要分布在微粒体(29.1±1.3%)和胞质(68.1±0.9%)组分之间,只有少量位于细胞核(2.8±0.5%)。给予雌二醇时,雌激素受体分布为:细胞核11.7±2.0、微粒体15.5±1.3和胞质72.8±3.3%,在他莫昔芬组中,结果为:细胞核18.5±1.5、微粒体26.0±3.1和胞质55.5±3.4%,这表明相对于对照组和雌二醇处理组都有相对的转移。在用ZD 182,780处理的大鼠子宫中,结果与对照组非常相似。我们的结果表明,雌激素受体的亚细胞分布因所给予的药物而异,并且该受体可能并不位于单个亚细胞区室中。此外,ZD 182,780-雌激素受体复合物的核摄取似乎被阻断,可能是由于受体二聚化受损。就他莫昔芬而言,受体的细胞内转运似乎也被阻断,可能是由于受体在细胞核中的滞留,因此表明他莫昔芬必须在受体二聚化后的一个步骤中损害雌激素受体功能。